Of these primary breast tumors, 63.4% (n = 40) of patients had luminal type tumors, 23.8% (n = 15) had HER2 amplification, 6.34% (n = 4) were triple-negative subtype, and 6.34% (n = 4) were classified as uncertain. Here, ERBB2 is linked to breast neoplasm.